Symbols

OABI

OmniAb·NASDAQ

--(--)

OABI fundamentals

OABI Q4 2025 Earnings

OmniAb (OABI) released its earnings on Mar 4, 2026: revenue was 8.38M (YoY -22.47%), missed estimates; EPS was -0.11 (YoY +8.33%), missed estimates.

Revenue / YoY

8.38M

-22.47%

EPS / YoY

-0.11

+8.33%

Report date

Mar 4, 2026

OABI Earnings Call Summary for Q4,2025

Partnership Expansion: 107 partners and 407 active programs, with 84 new additions in 2025, driven by innovative technologies.
Clinical Progress: 25 program advancements, including 4 entering phase 1 trials and 1 reaching registration.
Financial Outlook: 2026 guidance of $25-30 million revenue and $80-85 million expenses, with a path to cash flow positivity.
Technology Growth: xPloration and OmniUltra are key drivers, with 2 instruments deployed and strong partner interest.
Revenue Streams: $3 billion in milestones and a 3.4% average royalty rate, with potential for higher economics in new tech.

Earnings

EPS

Revenue

Revenue & Expenses

OABI has released its 2025 Q4 earnings report, with revenue of 8.38M, reflecting a YoY change of -22.47%, and net profit of -14.18M, showing a YoY change of -8.50%. The Sankey diagram below clearly presents OABI's revenue sources and cost distribution.

Key Indicators

OmniAb (OABI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

OmniAb (OABI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

OmniAb (OABI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

OmniAb (OABI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown